Nazarian et al. [38] have shown in a very recent study that metastatic prostate cancer patients presented decreased circulating DPPIV activity while protein levels were similar with respect to patients with localized primary tumor. This evidence concerns the gene DPP4 and metastatic prostate carcinoma.